Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer

Summary

This pilot clinical trial studies vorinostat before surgery in treating patients with triple-negative breast cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving enzyme inhibitor therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed

Timeline

Start

2012-10

Primary completion

2014-10

Completion

2015-10

Drugs

Indications